By including an interaction term—“tissue (1 = CRC, 0 = normal) × KRAS mutation status (1 = mutation, 0 = wild-type)” in the ANOVA model(s), we also asked if the magnitude of the differential expression of a given pathway was significantly different in the presence or absence of KRAS mutation in the tumor. This evidence concerns the gene KRAS and colorectal carcinoma.